Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors
Why invest in PREV?
PreveCeutical Medical Inc: THE INVESTMENT CASE

PreveCeutical Medical bidding to be big player in preventive healthcare

Van Deventer aims to grow the firm's valuation from its current $40mln market cap to $1bn plus in the next few years
PreveCeutical Medical bidding to be big player in preventive healthcare
INVESTMENT OVERVIEW: PREV The Big Picture
Grabbing the market - The firm has been working on the venom from the Caribbean Blue Scorpion

In a world where preventive medicine is gaining so much traction, PreveCeutical Medical Inc (CSE:PREV, OTCQB:PRVCF) is bidding to grab a large share of this massive pie.

"Medicine has been, basically, you've cut yourself, you put a Band-Aid on. We are doing the opposite. We're putting a skin coating on you so you can cut yourself," explains Stephen Van Deventer, chief executive at the new Canada-listed start up, on the firm's basic focus.

He describes his as a 'preventive healthcare' company, which sets itself apart from rest of the field due, mainly, to its world class management and cutting edge technologies.

Promising upside..

And the upside for investors looks promising too.

Van Deventer aims to grow the firm's valuation from its current $40mln market cap to $1bn plus in the next few years simply via its intellectual property (IP).

The firm has several programs on the go but among the most eye-catching perhaps is its work on the venom from the Caribbean Blue Scorpion, which has been shown to impact aggressive cancers, such as breast and brain.

Van Deventer said he came across a doctor, who for over 15 years, treated over 10,000 people combined with the venom for cancer and arthritis in the Dominican Republic and Cuba with great success.

PreveCeutical's Chief Science Officer Dr Mak Jawadekar is now directing a pre-clinical research and development program to synthesize the venom, to register the synthetic product as an IND (Investigational New Drug)

The company is already selling CELLB9 on the internet -  a dietatary supplement treatment containing peptides from the scorpion, the aim is to increase revenues considerably by a marketing campaign.

Targetting Far East and Middle East..

Markets aimed at initially for the venom products will be in the Far East and Middle East, while a version for pets is being put together for North America and the West, where Van Deventer says people are not so amenable to the venom as a treatment idea.

Elsewhere, and here's the big one.... the group's dual gene therapy has 'massive' potential, says Van Deventer, as it represents a potential cure for both diabetes and obesity.

These are arguably the two biggest health problems plaguing our planet today and have a US$1.3trn a year financial impact to the planet, suggests the company boss.

The firm has found out what gene pre-disposes a person to have the conditions and is now working on a gene -silencing technology.

"We are less than four years away from proving that and applying for an IND (investigational new drug)," explains Van Deventer.

And these are not the only irons in the fire. The group also signed a letter of intent in August on a painkiller, it says, is stronger than Fentanyl and morphine, in a deal which should close this month (October).

It is non-addictive, and should have a fairly quick route to market, reckons Van Deventer.

Delivering patented system..

Last but not least, the firm's Sol-Gel program is delivering a patented system, which can deliver any kind of drug, but the focus now is cannabinoids, via the nose and can be used in adults and children too.

The benefit is that as the gel stays in the naval cavity and is released, bypasses the liver, kidney’s and digestive track, and so smaller amounts of the drug can be used, costing less with greater efficiency.

The program received a huge boost last month, when it struck a research and development supply deal with a licensed Canadian producer (LP) of medical cannabis. The LP will supply PreveCeutical with cannabis oil and dried cannabis plant extract.

An import permit is expected this year so Preveceutical can begin importing cannabis from Canada to Australia so it can start developing the treatments.

To sum up for investors, Van Deventer says investors should look at the strength of the management team he has assembled to assess the group's potential.

"None of our people would sign up if they thought it would be a failure. Let’s bet on the jockey’s not the horse, however in this case we have both the Jockey’s and horses." he suggests.

That list of management includes Dr Mak Jawadekar, who  was with drugs giant Pfizer for 28 years. Dr Harry Parekh, chief research officer, is a senior lecturer at the University of Queensland, Australia, and Brian Harris, VP of corporate development,  was the founder of what is now Ticketmaster.

So PreveCeutical's portfolio is certainly quite eye-catching and its plans to grow in a rapidly expanding market are ambitious. Preveceutical could certainly be  one to watch in coming months.

View full PREV profile View Profile

PreveCeutical Medical Inc Timeline

Related Articles

Cancer highlighted
July 10 2017
The collaboration will see PDS Biotechnology Corp and a subsidiary of Merck & Co Inc embark on a new clinical trial collaboration for metastatic head and neck cancer
cancer cells
July 12 2017
The US-based, London-listed healthcare group topped expectations with its latest results and analysts are tipping it for more success this year
picture of human skeleton
July 21 2017
Tissue Regenix is funding the acquisition with a placing at 10p to raise £40mln

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use